22 May 2013
Keywords: genentech, shares, dip, after, stroke, warning, predicted
Article | 05 February 2007
US biotehcnology firm Genentech says that its new wet age-related macular degeneration drug Lucentis (ranibizumab) might raise the risk
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 February 2007
21 May 2013
© 2013 thepharmaletter.com